Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuetie Dingchuan Gao
- Development stage
- Phase 2
- Lead developer
- Nanjing University of Chinese Medicine
- Administration
- Topical
01
Overview
Xuetie Dingchuan Gao is a traditional Chinese medicine (TCM) medicated plaster developed by the Nanjing University of Chinese Medicine for the treatment of chronic persistent bronchial asthma, specifically the 'cold wheezing' pattern. The therapy involves the application of the herbal plaster to specific acupuncture points (acupoint application), allowing for the transdermal absorption of active botanical constituents. This approach aims to stabilize wheezing and alleviate asthma symptoms through the synergistic effects of its multi-ingredient herbal formulation. It has been studied in Phase 2 clinical trials in China to evaluate its efficacy and safety against placebo-like simulants in adult patients.
Beyond the preview
Go deeper on Xuetie Dingchuan Gao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xuetie Dingchuan Gao.